

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOEHRINGER INGELHEIM  
PHARMACEUTICALS INC.,  
BOEHRINGER INGELHEIM  
INTERNATIONAL GMBH and  
BOEHRINGER INGELHEIM  
PHARMA GMBH & CO. KG,

Plaintiffs,

v.

BIOCON LIMITED, BIOCON  
PHARMA, INC. AND BIOCON  
PHARMA LIMITED,

Defendants.

C.A. No. 25-523-CFC

**ANDA CASE**

**STIPULATION AND [PROPOSED] ORDER EXTENDING  
TIME**

In order to accommodate unforeseen personal issues involving outside counsel for Biocon Limited, Biocon Pharma, Inc. and Biocon Pharma Limited (“Biocon”), the parties hereby stipulate and agree, subject to the approval of the Court, that the deadline for Biocon to make its initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) (D.I. 15 at ¶ 3; D.I. 18) and to produce an up to date version of Biocon’s ANDA No. 220117 and any related FDA correspondence (D.I. 15 at ¶ 4) be extended from September 17, 2025 to September 29, 2025.

Dated: September 18, 2025

**MORRIS, NICHOLS, ARSHT &  
TUNNELL LLP**

/s/ Megan E. Dellinger

Brian P. Egan (#6227)  
Megan E. Dellinger (#5739)  
1201 North Market Street  
P.O. Box 1347  
Wilmington, DE 19899  
(302) 658-9200  
began@morrisnichols.com  
mdellinger@morrisnichols.com

*Attorney for Plaintiffs*

**SMITH, KATZENSTEIN &  
JENKINS, LLP**

/s/ Daniel A. Taylor

Neal C. Belgam (No. 2721)  
Daniel A. Taylor (No. 6934)  
1000 N. West Street, Suite 1501  
Wilmington, DE 19801  
(302) 652-8400  
nbelgam@skjlaw.com  
dtaylor@skjlaw.com

*Attorneys for Defendants*

IT IS SO ORDERED this \_\_\_\_ day of September, 2025.

\_\_\_\_\_  
The Honorable Colm F. Connolly  
Chief United States District Court Judge